Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287256 · ClinicalTrials.gov registry record · Phase 1
Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05287256: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT05287256 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05287256, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The current study will investigate the subjective, physiological, and cognitive performance effects of inhaled and orally ingested Delta-8 tetrahydrocannabinol (THC) in comparison to both placebo and Delta-9 THC. The purpose of this study is to assess the effects of Delta-8 THC as compared to placebo and Delta-9 THC. Oral fluid, urine, blood, and hair specimens will be collected from participants.
Primary Outcome
Subjective drug effect ratings (0-100) will be collected with the Drug Effect Questionnaire, with 0 being no effect and 100 being maximum effect.
Interventions
- DRUG Oral Placebo
- DRUG Oral Delta-8-THC Cannabis
- DRUG Oral Delta-9-THC Cannabis
- DRUG Vaporized Delta-8-THC Cannabis
- DRUG Vaporized Delta-9-THC Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-05-23 |
| Est. Completion | 2024-10-02 |
| Phase | Phase 1 |
What the finished NCT05287256 record still lists
NCT05287256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 5 interventions - of which Oral Placebo is the first listed.
NCT05287256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05287256 about?
NCT05287256 is a clinical study titled "Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC". The current study will investigate the subjective, physiological, and cognitive performance effects of inhaled and orally ingested Delta-8 tetrahydrocannabinol (THC) in comparison to both placebo and Delta-9 THC. The purpose of this study is to assess the effects of Delta-8 THC as compared to placeb...
What is the current status of trial NCT05287256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-05-23. Estimated completion is 2024-10-02.
What interventions are being tested in trial NCT05287256?
The interventions under investigation include: Oral Placebo (DRUG), Oral Delta-8-THC Cannabis (DRUG), Oral Delta-9-THC Cannabis (DRUG), Vaporized Delta-8-THC Cannabis (DRUG), Vaporized Delta-9-THC Cannabis (DRUG).
Who is sponsoring clinical trial NCT05287256?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05287256's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI